Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

onology

- PMLiVE

Boehringer’s coughing beat box drives its message home

Throat hacking performance raises awareness of lung cancer symptom

Projects selected for MSD-backed digital accelerator

Disease-specific mobile apps among those winning support from Velocity Health

- PMLiVE

UK patients get early access to AZ’s lung cancer drug Tagrisso

The treatment is the fourth made available under the EAMS

- PMLiVE

Pfizer’s Xalkori approved for wider use in Europe

Labelupdate gives the lung cancer therapy a new first-line indication

- PMLiVE

Merck & Co posts positive hepatitis C data

Elbasvir/grazoprevir achieves high cure rates for patients who inject drugs

- PMLiVE

AZ sets price of new lung cancer drug Tagrisso

Price tag of $150,000 per year given

- PMLiVE

Merck seeks oasis in CETP inhibitor desert

Pledgesto continue anacetrapib trials despite series of failures in its class

- PMLiVE

Merck defeated in antibiotic patent case in US

Loses four patents protecting Cubicin from generic competition

- PMLiVE

At long last, Merck gets FDA panel backing for Bridion

Unanimous vote in favour of drug suggest it is back on course for approval

- PMLiVE

US government probes Lilly and Merck over drug pricing

Department of Justice investigates drug pricing with regard to Medicaid programme

- PMLiVE

Merck KGaA and Pfizer move avelumab into late-stage trials

Begin phase III studies of the monoclonal antibody in lung cancer

- PMLiVE

Boehringer takes third-generation NSCLC drug into pivotal trials

Startsphase II study of BI 1482694 in patients who test positive for T790M mutation

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links